CTIC CTI BioPharma Corp.

0  -1%
Previous Close 3.99
Open 3.98
Price To book 8.40
Market Cap 110.78M
Shares 28,045,000
Volume 25,977
Short Ratio 12.29
Av. Daily Volume 126,756

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Top-line data from confirmatory trial required for full EMA approval due by end of 2017.
B-cell non-Hodgkin lymphoma
PERSIST-2 data released August 2016. One of two primary endpoints met. Announced January 5, 2017 removal of clinical hold. Additional trial to commence 2Q 2017.
Pacritinib - PAC203
Phase 3 trial potentially in the pipeline.
Older patients with AML or high-risk myelodysplastic syndrome (MDS) - cancer
Phase 3 - noted July 2016 that unlikely to have survival benefit
Ovarian cancer

Latest News

  1. Edited Transcript of CTIC earnings conference call or presentation 2-Mar-17 9:30pm GMT
  2. ETFs with exposure to CTI BioPharma Corp. : March 30, 2017
  3. CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017
  4. CTI BioPharma to Present at the 29th Annual ROTH Conference
  5. CTI BioPharma reports 4Q loss
  6. CTI BioPharma Reports Fourth Quarter and Full Year 2016 Financial Results
  7. CTI BioPharma hires new CEO
  8. CTI BioPharma Announces Appointment of Hematology/Oncology Clinical Expert Adam Craig, M.D., Ph.D., as President and CEO
  9. CTI BioPharma to Report Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017
  10. CTI BioPharma to Present at the BIO CEO & Investor Conference
  11. CTI BioPharma Appoints Leading BioPharma Executive Michael Metzger To Board Of Directors
  12. Latest Reports on Recent Market Movers: 3D Systems and CTI BioPharma
  13. CTI BioPharma Announces Progress Of Lead Programs And Strategic Objectives For 2017
  14. CTI Biopharma stock revived after FDA ruling, reverse stock split
  15. Why CTI BioPharma Corp. Stock Popped Today
  16. CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib
  17. ETFs with exposure to CTI BioPharma Corp. : January 4, 2017
  18. CTI BioPharma Corp. breached its 50 day moving average in a Bullish Manner : CTIC-US : January 4, 2017
  19. ETFs with exposure to CTI BioPharma Corp. : December 13, 2016